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Summary:
TUBERSOL®, a product of Sanofi Pasteur Limited, is in shortage nationwide until at least the end of May 
2013. TUBERSOL® is one of two purified-protein derivative (PPD) tuberculin products that are licensed 
by the United States Food and Drug Administration (FDA). The manufacturer notified CDC that 50-dose 
vials of TUBERSOL® are unavailable and that the supplies of 10-dose vials will be limited. This notice 
advises public health officials, clinicians, and workers in occupational health and infection control about 
how to adapt to the shortage.
JHP Pharmaceuticals, LLC, the manufacturer of APLISOL®, the other PPD tuberculin product that is 
licensed by FDA, has notified FDA that the product is on allocation and is available in restricted quantity. 
Acute local shortages of APLISOL® are being reported to CDC by healthcare providers who switch from 
TUBERSOL® to APLISOL®.
Background:
Two kinds of immunological methods are used for detecting Mycobacterium tuberculosis infection: 
tuberculin skin tests (TSTs) and interferon-Y release assay (IGRA) blood tests. The indications for using 
these tests are the same for the two methods, although one or the other method is preferred for certain 
populations (1), and this could play a factor in setting priorities when one of the methods is unavailable. 
Together, these tests are the only means for detecting latent M. tuberculosis infection, and they contribute 
to diagnosing tuberculosis (TB) disease. When findings such as chest radiography and mycobacterial 
cultures are sufficient for confirming or excluding the TB diagnosis, the results from a TST or an IGRA 
blood test might not be needed (2). However, most TB cases in the United States are diagnosed with a 
set of findings including results from one of these tests. When TB disease is strongly suspected, specific 
treatment should be started regardless of results from tuberculin skin test or an IGRA blood test (1,3).
In controlled studies, the concordance between TST results from TUBERSOL® and APLISOL® is high. 
The concordance between results from a TST and an IGRA blood test or between results from the two 
commercial IGRA blood tests is lower (1).
Recommendations:
CDC recommends any of three general approaches for addressing the shortages of tuberculin skin test 
antigens:
1. Substitute IGRA blood tests for TSTs. The costs associated with using the blood tests can be 
greater than the cost of TSTs. The blood tests require phlebotomy, preparation of blood 
specimens, and specific laboratory services for analysis. Thus, these tests are not available in all 
practice settings. Clinicians who use the IGRA blood tests should be aware that the criteria for 
test interpretation are different than the criteria for interpreting TSTs (1).
2. Allocate TSTs to priority indications, such as TB contact investigations, as determined by public 
health authorities. This might require deferment of testing some persons. CDC does not 
recommend testing persons who are not at risk of TB (4).
3. Substitute APLISOL® for TUBERSOL® for skin testing. In cross-sectional studies, the two 
products give similar results for most patients. Shortages of APLISOL® are expected to become 
more widespread, thus limiting the feasibility of this approach.
Some surveillance programs for TB infection control rely on routine serial TSTs. Switching products or 
methods might make serial changes in test results difficult to interpret: the apparent conversions of results 
from negative to positive or reversions from positive to negative could be caused by inherent inter-product
or inter-method discordance (1,5). In settings with a low likelihood of TB exposure, the deferment of 
routine serial testing should be considered in consultation with public health and occupational health 
authorities.
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The Centers for Disease Control and Prevention (CDC) protects people’s health and safety by preventing and 
controlling diseases and injuries; enhances health decisions by providing credible information on critical health 
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